SEARCH

SEARCH BY CITATION

References

  • Arrive E, Newell ML, Ekouevi DK et al. (2007) Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. International Journal of Epidemiology 36, 10091021.
  • Badri M, Lawn SD & Wood R (2008) Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infectious Diseases 8, 89.
  • Bisson GP, Gross R, Bellamy S et al. (2008) Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Medicine 5, e109.
  • Chi BH, Chintu N, Lee A, Stringer EM, Sinkala M & Stringer JS (2007a) Expanded Services for the Prevention of Mother-to-Child HIV Transmission: field Acceptability of a Pilot Program in Lusaka, Zambia. Journal of Acquired Immune Deficiency Syndromes 45, 125127.
  • Chi BH, Sinkala M, Stringer EM et al. (2007b) Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21, 957964.
  • Chi BH, Cantrell RA, Zulu I et al. (2009a) Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. International Journal of Epidemiology 38, 746756.
  • Chi BH, Ellis GM, Chintu N et al. (2009b) Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention. AIDS Research and Human Retroviruses 25, 10991106.
  • Coovadia A, Hunt G, Abrams EJ et al. (2009) Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clinical Infectious Diseases 48, 462472.
  • Flys T, Nissley DV, Claasen CW et al. (2005) Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. Journal of Infectious Diseases 192, 2429.
  • Fusco H, Hubschman T, Mweeta V et al. (2005) Electronic patient tracking supports rapid expansion of HIV care and treatment in resource-constrained settings. [Abstract MoPe11 2C37] 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil.
  • Goldman JD, Cantrell RA, Mulenga LB et al. (2008) Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Research and Human Retroviruses 24, 10311035.
  • Guay LA, Musoke P, Fleming T et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354, 795802.
  • Jackson JB, Musoke P, Fleming T et al. (2003) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362, 859868.
  • Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al. (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. New England Journal of Medicine 351, 229240.
  • Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al. (2009) 4-year clinical and therapeutic consequences of intrapartum single-dose nevirapine for the prevention of perinatal HIV in women who subsequently intiated a nevirapine-based ART. [Abstract 954] 16th Conference on Retroviruses and Opportunistic Infections, Montreal.
  • Killam WP, Tambatamba BC, Chintu N et al. (2010) Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation. AIDS 24, 8591.
  • Lockman S (2009) Lopinavir/ritonavir + tenofovir/emtricitabine is superior to nevirapine + tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 (“OCTANE”) [Abstract 94LB]. 16th Conference on Retroviruses and Opportunistic Infections, Montreal.
  • Lockman S, Shapiro RL, Smeaton LM et al. (2007) Response to antiretroviral therapy after a single peripartum dose of nevirapine. New England Journal of Medicine 356, 135147.
  • Lockman S, Smeaton L, Ogwu A et al. (2009) Long-term maternal and pediatric virologic outcomes on nevirapine-based HAART following receipt of peripartum single-dose nevirapine (sdNVP) or placebo Botswana [Abstract 955]. 16th Conference on Retroviruses and Opportunistic Infections, Montreal.
  • Mwango A, Giganti M, Mulenga L et al. (2009) First-line tenofovir ART in Zambia. 16th Conference on Retroviruses and Opportunistic Infections, Montreal.
  • Reynolds SJ, Nakigozi G, Newell K et al. (2009) Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 23, 697700.
  • Stringer EM, Sinkala M, Stringer JS et al. (2003) Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 17, 13771382.
  • Stringer JS, Zulu I, Levy J et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Journal of the American Medical Association 296, 782793.
  • Stringer JS, Mcconnell MS, Kiarie J et al. (2010) Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country prospective cohort study. PLoS Medicine 7, e1000233.
  • Troyer RM, Lalonde MS, Fraundorf E et al. (2008) A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Research and Human Retroviruses 24, 235250.
  • WHO (2006) Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants in Resource-Limited Settings: Towards Universal Access. WHO, Geneva.